AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03796715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Red Cell Distribution Width (RDW)
Description: A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
Study NCT03796715 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Presepsin (sCD14-ST)
Description: : A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
Study NCT03328845 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apidra
Description: Ultrarrapid insulin that the patient had already and dose adjustement to obtain postprandial glycaemia levels \< 150 mg/dl
Study NCT04332679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - control group
Description: 20 patients treated by means of a dense PTFE (d-PTFE) titanium-reinforced membrane (Cytoplast Ti-250XL; Osteogenics Biomedical) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
Study NCT04332679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B - Test group
Description: 20 patients treated by means of Ti mesh (Trinon Titanium; Karlsruhe, Germany) and cross-linked collagen membrane (Osseoguard, Zimmer Biomet, Warsaw, IN, USA) and simultaneous implants placement (BT SAFE; Biotec srl, Vicenza, Italy).
Study NCT00286962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIP 2007C implantable insulin pump
Description: Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
Study NCT00286962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous subcutaneous insulin infusion (CSII) or MDI
Study NCT03758794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive lecture
Description: an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
Study NCT03758794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: online education
Description: an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
Study NCT04233983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Endometriosis Surgery
Description: Patient with ERROR(endometrioma related reduction in ovarian reserve), and endometrioma larger than 3 cm diameter will be operated after IVF\&ICSI procedure. Operation will be done by senior surgeons of our department. Laparoscopic endometrioma operation procedure consists of excision of endometrioma cyst with its capsule from ovary without using any electric modality to prevent ovarian damage.
Study NCT03146325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE
Description: A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
Study NCT03146325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MATCHING PLACEBO
Description: TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
Study NCT03402321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin Sponge Sheet
Description: sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
Study NCT03402321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvogyl
Description: paste form with analgesic action to protect the palatal donor site and help to relief pain
Study NCT00478322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of 100 mg BID
Study NCT00478322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB013739
Description: INCB013739 100 mg BID
Study NCT00093132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satraplatin
Description: Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
Study NCT01250847 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Quetiapine(Seroquel-XR) 50~800mg a day
Description: The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
Study NCT01250847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine(Seroquel-XR) 50~800mg a day
Description: The only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.
Study NCT02181998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full dose tenecteplase
Study NCT02181998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full dose tenecteplase
Study NCT02181998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractioned heparin
Study NCT02181998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Study NCT01093170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNA-144101
Description: Intravitreous administration of RNA-144101
Study NCT00696228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00696228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MUFA
Description: MUFA
Study NCT00696228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA
Description: PUFA
Study NCT00696228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SFA
Description: SFA
Study NCT02223364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral nerve blocks with Bupivacaine
Description: Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
Study NCT02223364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection with Ropivacaine
Description: Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
Study NCT02223364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection with liposomal bupivacaine
Description: Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS-r
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-r
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS-r
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS-r
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS-s
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS-s
Description: The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS-s
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
Study NCT04092088 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TENS-s
Description: Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
Study NCT02683148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Study NCT02683148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-67 validated survey
Description: * Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~* 7 questions with answers ranging from 0=Not At All to 4 = Very Much.
Study NCT01473394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-matched placebo
Description: Dose-matched placebo was supplied as tablets.
Study NCT01473394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: Vilazodone was supplied as tablets.
Study NCT00803309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha-2b
Description: 1.5 µg/kg once weekly, syringe, 24 weeks
Study NCT00803309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800-1400 mg per os, daily, tablets, 24 weeks
Study NCT00803309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated Interferon alpha-2b
Description: 1.5 µg/kg once weekly, syringe, 12 weeks
Study NCT00803309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 800-1400 mg per os, daily, tablets, 12 weeks
Study NCT02398370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
Study NCT01522235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double blinded IVIg
Description: Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
Study NCT01522235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Double blinded Placebo
Description: Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
Study NCT01522235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Blinded IVIg
Description: This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
Study NCT01522235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Single Blinded IVIg
Description: This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
Study NCT02342977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will randomly receive placebo
Study NCT02342977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Patients will randomly receive lacosamide
Study NCT04038554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Feces and saliva analysis
Description: Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
Study NCT03742817 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study NCT03742817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study NCT03853902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Program
Description: Mindfulness Program
Study NCT03853902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Program
Description: Mindfulness Program
Study NCT02498509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-342
Description: treatment for 4 weeks after randomization
Study NCT02498509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Description: treatment for 4 weeks after randomization
Study NCT02498509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocabastine HCL
Description: treatment for 4 weeks after randomization
Study NCT02673242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold IMT Philips Respironics
Description: Inspiratory muscle training
Study NCT01451164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: orally administered once daily
Study NCT01451164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally administered once daily
Study NCT03402347 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-ionising radiation
Description: Laser regimes will be applied to ex vivo skin samples.
Study NCT03409939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aromatic Amino Acid Intake
Description: Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
Study NCT01985958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT03313011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing protocol for the study
Description: All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
Study NCT04413383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Curved Iris Scissors
Description: Aesculap Curved Iris Scissors
Study NCT04413383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wuennenberg Modified Curved Iris Scissors
Description: Modified Silent Curved Iris Scissors
Study NCT04413383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors
Description: Patients experience both types of scissors
Study NCT01821950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga during physical education
Description: 12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
Study NCT03955965 — intervention group
Intervention type: OTHER
Intervention: Medication reconciliation
Description: No intervention was performed other than collecting data on patients' medical files
Study NCT03098017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short pasta (dry)
Description: 50g available carbohydrate portion of penne (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
Study NCT03098017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long pasta (dry)
Description: 50g available carbohydrate portion of spaghetti (\~71g uncooked) will be cooked according to package instructions and served with 500mL water
Study NCT03098017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Couscous
Description: 50g available carbohydrate portion of couscous (\~70g uncooked) will be cooked according to package instructions and served with 500mL water
Study NCT03098017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50g available carbohydrate portion of glucose monohydrate (\~55g) will be dissolved in 500mL water
Study NCT04412642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane, MEOF
Description: As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
Study NCT00722163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Study NCT00722163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: befriending
Study NCT03376373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neurofeedback
Description: real-time feedback on accuracy of emotion recognition
Study NCT02397291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannose
Description: A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
Study NCT02397291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Description: A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
Study NCT02397291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT04312841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Given PO
Study NCT00998348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
Study NCT03742817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: e-Cigarette
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study NCT01269255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 with Cisplatin
Description: SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~* Step 1: Chemotherapy; TS-1/CDDP #2 cycles~* Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~* Step 3: Surgery therapy
Study NCT04191122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COPESS
Description: The intervention includes brief psychotherapy to be delivered within primary care settings
Study NCT00717275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
Study NCT04240275 — intervention group
Intervention type: DEVICE
Intervention: Reliability of the G-Walk device in children with Cerebral Palsy
Description: The purpose of this study was to confirm the test-retest reliability of a commercially available body-worn sensor-G-Walk® sensor system-for spatiotemporal gait parameters in children with CP.~The children will be assessed with the G-Walk on two separate occasions.For the reliability analysis, the second measurement tests will be repeated 3 days after the first assessment.~The device is placed on an elastic belt and worn on the waist of the person being evaluated, with the center of the device at the fifth lumbar vertebrae. To ensure correct placement of the device, the L4-L5 intervertebral space will be palpated via the posterior superior iliac spines (SIPS).~After the accelerometer is placed, the children are asked to walk calmly at normal speed, on a 10 m track, whose boundaries will be determined with colored lines and to return to the starting position.